Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 5, 2026
MiniMed Group, Inc. (MMED)
A forensic read on MiniMed Group, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
4.3
Altman Z-score
Clean
Earnings quality
2
Forensic signals
$4.4B
Market cap
MiniMed Group, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 4.3, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-4%Return on invested capital.Return on invested capital is -4% in the latest fiscal year and slipping from -2% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+0.8%/yrShare-count dilution.Diluted share count changed +2% over the last 2 years to FY2026 (+0.8%/yr). Roughly flat — buybacks are about offsetting stock comp, not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.
Key fundamentals
Latest Revenue$3.10B
Revenue Growth YoY+14.3%
Net Margin-10.7%
Free Cash Flow$-420.0M
Return on Equity-9.2%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on MiniMed Group, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about MMED's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown